DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Pearce N, Beasley R, Crane J, et al. End of the New Zealand
asthma mortality epidemic. Lancet, 1995, 345:41–44.
Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of
carvedilol and metoprolol on clinical outcomes in patients with
chronic heart failure in the Carvedilol Or Metoprolol European
Trial (COMET): Randomised controlled trial. Lancet, 2003,
362:7–13.
Post SR, Hammond HK, Insel PA. β-Adrenergic receptors and
receptor signaling in heart failure. Annu Rev Pharmacol
Toxicol, 1999, 39:343–360.
Prakash A, Markham A. Metoprolol: a review of its use in
chronic heart failure. Drugs, 2000, 60:647–678.
Redington AE. Step one for asthma treatment: β 2
-agonists or
inhaled corticosteroids? Drugs, 2001, 61:1231–1238.
Reynolds NA, Lyseng-Williamson KA, Wiseman LR. Inhaled
salmeterol/fluticasone propionate. A review of its use in
asthma. Drugs, 2005, 65:1715–1734.
Ried LD, McFarland BH, Johnson RE, Brody KK. β-Blockers
and depression: the more the murkier? Ann Pharmacother,
1998, 32:699–708.
Robidoux J, Martin TL, Collins S. β-Adrenergic receptors and
regulation of energy expenditure: A family affair. Annu Rev
Pharmacol Toxicol, 2004, 44:297–323.
Rosei EA, Rizzoni D. Metabolic profile of nebivolol, a β-
adrenoceptor antagonist with unique characteristics. Drugs,
2007, 67:1097–1107.
Rosei EA, Rizzoni D, Comini S, Boari G. Nebivolol-Lisinopril
Study Group. Evaluation of the efficacy and tolerability of
nebivolol versus lisinopril in the treatment of essential arterial
hypertension: A randomized, multicentre, double blind study.
Blood Press Suppl, 2003, 1:30–35.
Rosen SG, Clutter WE, Shah SD, et al. Direct α-adrenergic stimulation
of hepatic glucose production in human subjects. Am
J Physiol, 1983, 245:E616–E626.
Rosendorff C. β-Blocking agents with vasodilator activity.
J Hypertens Suppl, 1993, 11:S37–S40.
Rozec B, Noireaud J, Trochu J, Gauthier C. Place of β 3
-
adrenoceptors among other β-adrenoceptor sub-types in the
regulation of the cardiovascular system. Arch Mal Coeur Vaiss,
2003, 96:905–913.
Ruffolo RR Jr. The pharmacology of dobutamine. Am J Med Sci,
1987, 294:244–248.
Ruffolo RR Jr, Hieble JP. Adrenoceptor pharmacology:
Urogenital applications. Eur Urol, 1999, 36(Suppl 1):17–22.
Salpeter SR. Cardioselective β blocker use in patients with
asthma and chronic obstructive pulmonary disease: An evidencebased
approach to standard of care. Respir Med, 2003,
24:564–572.
Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective betablockers
for chronic obstructive pulmonary disease. Cochrane
Database Syst Rev, 2005, CD003566.
Sandhu JS, Vaughan ED Jr. Combination therapy for the pharmacological
management of benign prostatic hyperplasia. Rationale
and treatment options. Drugs Aging, 2005, 22:901–912.
Santillo VM, Lowe F. Treatment of benign prostatic hyperplasia
in patients with cardiovascular disease. Drugs, 2006,
23:795–805.
Seale JP. Whither β-adrenoceptor agonists in the treatment of
asthma? Prog Clin Biol Res, 1988, 263:367–377.
Self T, Soberman JE, Bubla JM, Chafen CC. Cardioselective
β-blockers in patients with asthma and concomitant heart failure
or history of myocardial infarction: When do benefits outweigh
risks? J Asthma, 2003, 40:839–845.
Schmid-Schoenbein G, Hugli T. A new hypothesis for microvascular
inflammation in shock and multiorgan failure: Self-digestion
by pancreatic enzymes. Microcirculation, 2005, 12:71–82.
Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of
aortic dilatation and the benefit of long-term β-adrenergic
blockade in Marfan’s syndrome. N Engl J Med, 1994,
330:1335–1341.
Simon T, Mary-Krause M, Funck-Brentano C, et al. Bisoprolol
dose-response relationship in patients with congestive heart
failure: A subgroups analysis in the cardiac insufficiency bisoprolol
study (CIBIS II). Eur Heart J, 2003, 24:552–559.
Singh K, Communal C, Sawyer DB, Colucci WS. Adrenergic
regulation of myocardial apoptosis. Cardiovasc Res, 2000,
45:713–719.
Starke K, Gothert M, Kilbinger H. Modulation of neurotransmitter
release by presynaptic autoreceptors. Physiol Rev, 1989,
69:864–989.
Suissa S, Ernst P. Optical illusions from visual data analysis:
Example of the New Zealand asthma mortality epidemic. J Clin
Epidemiol, 1997, 50:1079–1088.
Swanson JM, Volkow ND. Serum and brain concentrations of
methylphenidate: implications for use and abuse. Neurosci
Biobehav Rev, 2003, 27:615–621.
Tam SW, Worcel M, Wyllie M. Yohimbine: A clinical review.
Pharmacol Ther, 2001, 91:215–243.
Tfelt-Hansen P. Efficacy of β-blockers in migraine. A critical
review. Cephalalgia, 1986, 6(Suppl 5):15–24.
Toda N. Vasodilating β-adrenoceptor blockers as cardiovascular
therapeutics. Pharmacol Ther, 2003, 100:215–234.
Varon J. Treatment of acute severe hypertension: current and
newer agents. Drugs, 2008, 68:283–297.
Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide
mononitrate compared with sclerotherapy for the prevention of
variceal rebleeding. N Engl J Med, 1996, 334:1624–1629.
Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology,
clinical efficacy and tolerability in the management of
spasticity associated with cerebral and spinal disorders. Drugs,
1997, 53:435–452.
Walle T, Webb JG, Bagwell EE, et al. Stereoselective delivery
and actions of β receptor antagonists. Biochem Pharmacol,
1988, 37:115–124.
Webers C, Beckers H, Nuijts R, Schouten J. Pharmacological
management of primary open-angle glaucoma second line
options and beyond. Drugs Aging, 2008, 25:729–759.
Witchitz S, Cohen-Solal A, Dartois N, et al. Treatment of heart
failure with celiprolol, a cardioselective β blocker with β-2
agonist vasodilator properties. The CELICARD Group. Am J
Cardiol, 2000, 85:1467–1471.
Wood JP, Schmidt KG, Melena J, et al. The β-adrenoceptor antagonists
metipranolol and timolol are retinal neuroprotectants:
Comparison with betaxolol. Exp Eye Res, 2003, 76:505–516.
Wuttke H, Rau T, Heide R, et al. Increased frequency of
cytochrome P450 2D6 poor metabolizers among patients with
metoprolol-associated adverse effects. Clin Pharmacol Ther,
2002, 72:429–437.
Zhu QM, Lesnick JD, Jasper JR, et al. Cardiovascular effects of
rilmedidine, moxonidine and clonidine in conscious wild-type
and D79N α 2A
-adrenoreceptor transgenic mice. Br J Pharmacol,
1999, 126:1522–1530.
333
CHAPTER 12
ADRENERGIC AGONISTS AND ANTAGONISTS